相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the cannabinoid receptor CB2 in a mouse model of 1-dopa induced dyskinesia
Peggy Rentsch et al.
NEUROBIOLOGY OF DISEASE (2020)
Apathy rating scores and beta-amyloidopathy in patients with Parkinson disease at risk for cognitive decline
Zhi Zhou et al.
NEUROLOGY (2020)
Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease
Stephanie Martins de Faria et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease
Glauce Crivelaro do Nascimento et al.
NEUROPHARMACOLOGY (2020)
More evidence of cannabis efficacy in restless legs syndrome
Imad Ghorayeb
SLEEP AND BREATHING (2020)
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Sinemyiz Atalay et al.
ANTIOXIDANTS (2020)
Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
Marina Peball et al.
ANNALS OF NEUROLOGY (2020)
Cannabis in patients with Parkinson's disease in Argentina. A cross sectional study
Federico Eduardo Micheli et al.
PARKINSONISM & RELATED DISORDERS (2020)
Cannabinoids in the Older Person: A Literature Review
William Beedham et al.
GERIATRICS (2020)
Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Nadia Montero-Oleas et al.
BMC COMPLEMENTARY MEDICINE AND THERAPIES (2020)
TSFM mutations cause a complex hyperkinetic movement disorder with strong relief by cannabinoids
Andreas Traschuetz et al.
PARKINSONISM & RELATED DISORDERS (2019)
Acute Illness Associated With Cannabis Use, by Route of Exposure An Observational Study
Andrew A. Monte et al.
ANNALS OF INTERNAL MEDICINE (2019)
Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Jose Alexandre S. Crippa et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2019)
Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease
Nathan Herrmann et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2019)
Pain in cervical dystonia: Evidence of abnormal inhibitory control
Michele Tinazzi et al.
PARKINSONISM & RELATED DISORDERS (2019)
Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
Carol A. C. Coupland et al.
JAMA INTERNAL MEDICINE (2019)
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Stefania Bonaccorso et al.
NEUROTOXICOLOGY (2019)
A Literature Review of Psychotropic Medications and Alcohol as Risk Factors for Falls in Community Dwelling Older Adults
Sarah Laberge et al.
CLINICAL DRUG INVESTIGATION (2019)
A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol:Δ9-Tetrahydrocannabiphorol
Cinzia Citti et al.
SCIENTIFIC REPORTS (2019)
Medical marijuana. What can we learn from the experiences in Canada, Germany and Thailand?
Jurgen Rehm et al.
INTERNATIONAL JOURNAL OF DRUG POLICY (2019)
State marijuana laws and opioid overdose mortality
Stanford Chihuri et al.
INJURY EPIDEMIOLOGY (2019)
CB1 Receptor Signaling in the Brain: Extracting Specificity from Ubiquity
Arnau Busquets-Garcia et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Singular Location and Signaling Profile of Adenosine A(2A)-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum
Estefania Moreno et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Chronic pain and pain processing in Parkinson's disease
Pierre J. Blanchet et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2018)
The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report
Donald I. Abrams
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2018)
Cannabis Addiction and the Brain: a Review
Amna Zehra et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2018)
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease
Dan P. Covey et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Examination of the effects of cannabinoid ligands on decision making in a rat gambling task
Jacqueline-Marie N. Ferland et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2018)
Cannabinoids for Treatment of Dystonia in Huntington's Disease
Carsten Saft et al.
JOURNAL OF HUNTINGTONS DISEASE (2018)
Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease
A. Shohet et al.
EUROPEAN JOURNAL OF PAIN (2017)
Labeling Accuracy of Cannabidiol Extracts Sold Online
Marcel O. Bonn-Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome
Elia Abi-Jaoude et al.
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES (2017)
Evidence for the Risks and Consequences of Adolescent Cannabis Exposure
Amir Levine et al.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (2017)
A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice
Andras Bilkei-Gorzo et al.
NATURE MEDICINE (2017)
Mechanisms contributing to cognitive deficits in cannabis users
Romina Mizrahi et al.
NEUROPHARMACOLOGY (2017)
Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review
Samantha J. Broyd et al.
BIOLOGICAL PSYCHIATRY (2016)
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease
Jose Luis Lopez-Sendon Moreno et al.
JOURNAL OF NEUROLOGY (2016)
Keep off the grass? Cannabis, cognition and addiction
H. Valerie Curran et al.
NATURE REVIEWS NEUROSCIENCE (2016)
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action
Mauricio dos-Santos-Pereira et al.
NEUROBIOLOGY OF DISEASE (2016)
Microglia activation states and cannabinoid system: Therapeutic implications
M. Mecha et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor
Hassan Abbassian et al.
PHYSIOLOGY & BEHAVIOR (2016)
Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses
Will Lawn et al.
PSYCHOPHARMACOLOGY (2016)
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
Nora D. Volkow et al.
JAMA PSYCHIATRY (2016)
Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson's Disease Patients in Colorado
Taylor Andrew Finseth et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2015)
The Therapeutic Potential of Cannabinoids for Movement Disorders
Benzi Kluger et al.
MOVEMENT DISORDERS (2015)
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats
A. A. Martinez et al.
NEUROBIOLOGY OF DISEASE (2015)
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series
M. H. N. Chagas et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
The effects of endocannabinoid signaling on network activity in developing and motor circuits
Peter Wenner
NEURONS, CIRCUITRY, AND PLASTICITY IN THE SPINAL CORD AND BRAINSTEM (2013)
The Pharmacologic and Clinical Effects of Medical Cannabis
Laura M. Borgelt et al.
PHARMACOTHERAPY (2013)
CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity
Emmanuel S. Onaivi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana
J. Michael Bostwick
MAYO CLINIC PROCEEDINGS (2012)
Endocannabinoids in nervous system health and disease: the big picture in a nutshell Introduction
Stephen D. Skaper et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
The evolution and comparative neurobiology of endocannabinoid signalling
Maurice R. Elphick
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease
Cristina Blazquez et al.
BRAIN (2011)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
Mateus M. Bergamaschi et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease
E. L. Scotter et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
A brief history of levodopa
Oleh Hornykiewicz
JOURNAL OF NEUROLOGY (2010)
The Role of Endocannabinoid Signaling in Motor Control
A. El Manira et al.
PHYSIOLOGY (2010)
The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease
J. E. Kelsey et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Cannabidiol for the treatment of psychosis in Parkinson's disease
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease
Adrienne Curtis et al.
MOVEMENT DISORDERS (2009)
Effects of the National Youth Anti-Drug Media Campaign on Youths
Robert Hornik et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2008)
Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats
Moises Garcia-Arencibia et al.
NEUROSCIENCE LETTERS (2008)
Cannabinoids and neuroprotection in basal ganglia disorders
Onintza Sagredo et al.
MOLECULAR NEUROBIOLOGY (2007)
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease:: Importance of antioxidant and cannabinoid receptor-independent properties
Moises Garcia-Arencibia et al.
BRAIN RESEARCH (2007)
Cannabinoid-based drugs as anti-inflammatory therapeutics
TW Klein
NATURE REVIEWS IMMUNOLOGY (2005)
Cannabis sativa and dystonia secondary to Wilson's disease
MCU Roca et al.
MOVEMENT DISORDERS (2005)
Cannabis for dyskinesia in Parkinson disease - A randomized double-blind crossover study
CB Carroll et al.
NEUROLOGY (2004)
Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease
V Mesnage et al.
CLINICAL NEUROPHARMACOLOGY (2004)
Role of endogenous cannabinoids in synaptic signaling
TF Freund et al.
PHYSIOLOGICAL REVIEWS (2003)
Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:: A 6-week randomized trial
KR Müller-Vahl et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (Δ9-THC):: No influence on neuropsychological performance
KR Müller-Vahl et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia
A Richter et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
I Lastres-Becker et al.
SYNAPSE (2002)
Treatment of Tourette's syndrome with Delta(9)-tetrahydrocannabinol (THC): A randomized crossover trial
KR Muller-Vahl et al.
PHARMACOPSYCHIATRY (2002)
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
SH Fox et al.
MOVEMENT DISORDERS (2002)
分享论文
